1.70
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BTAI Giù?
Forum
Previsione
Bioxcel Therapeutics Inc Borsa (BTAI) Ultime notizie
Mizuho slashes BioXcel Therapeutics stock price target to $2 from $16 - Investing.com
What is the risk reward ratio of investing in BioXcel Therapeutics Inc. stockTriple-digit wealth increases - jammulinksnews.com
What are BioXcel Therapeutics Inc. company’s key revenue driversCapitalize on market trends with confidence - jammulinksnews.com
What are the technical indicators suggesting about BioXcel Therapeutics Inc.Exceptional profit velocity - jammulinksnews.com
Is it the right time to buy BioXcel Therapeutics Inc. stockBuild a winning investment portfolio - jammulinksnews.com
Does BioXcel Therapeutics Inc. stock perform well during market downturnsDiscover breakthrough stocks before the crowd - jammulinksnews.com
How high can BioXcel Therapeutics Inc. stock price go in 2025Free Discussion Group - Metal.it
What analysts say about BioXcel Therapeutics Inc. stockFree Predictions - PrintWeekIndia
BioXcel Therapeutics Inc. Stock Analysis and ForecastRapid wealth accumulation - PrintWeekIndia
Is BioXcel Therapeutics Inc. a good long term investmentBreakthrough capital growth - PrintWeekIndia
Is BioXcel Therapeutics Inc. stock a good hedge against inflationBreakneck growth rates - jammulinksnews.com
What drives BioXcel Therapeutics Inc. stock priceFree Stock Market Real-Time Monitoring - Autocar Professional
BioXcel stock holds Buy rating at H.C. Wainwright ahead of FDA meeting - Investing.com Canada
BioXcel Therapeutics: Buy Rating Affirmed Amidst Pre-sNDA Submission and Upcoming SERENITY At-Home Trial Results - TipRanks
BioXcel Therapeutics Submits Pre-Supplemental New Drug - GlobeNewswire
Bioxcel Therapeutics' Strategic Move to Expand IGALMI for At-Home Use: Assessing the Market Opportunity and Regulatory Pathway for First-in-Class Agitation Treatment in Outpatient Mental Health - AInvest
BioXcel schedules FDA meeting for IGALMI outpatient use expansion - Investing.com
BioXcel schedules FDA meeting for IGALMI outpatient use expansion By Investing.com - Investing.com Nigeria
BTAI files pre-sNDA to expand IGALMI label for home use | BTAI SEC FilingForm 8-K - Stock Titan
Bioxcel Therapeutics Submits Pre-Supplemental New Drug Application Meeting Package In Support Of Potential Label Expansion For Igalmi - TradingView
First-Ever At-Home Agitation Drug: FDA to Review IGALMI for 23M Patient Market Opportunity - Stock Titan
why bioxcel therapeutics inc. stock attracts strong analyst attentionStable Growth Stock Picks - Newser
What makes BioXcel Therapeutics Inc. stock price move sharplyAI Powered Stock Call - Newser
BioXcel Therapeutics Receives Steady Buy Rating from Lucid Capital Markets, Price Target Unchanged at $66.00 - AInvest
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):